EFTA02708214.pdf

From: DS Sent: Tuesday, June 25, 2013 6:59 PM To: Jeffrey Epstein Subject: Fwd: Immodulon Attachments: Immodulon NewsletterJan2013.pdf, Untitled attachment 00064.htm Begin forwarded message: From: Robert Pfeiffer Date: 24 June 2013 12:51:27 CEST To: "• Subject: FW: Immodulon From: Charles Akle Sent: Wednesday, June 19, 2013 1:07:58 PM To: Robert Pfeiffer Cc: Bilyard Kevin Subject: Immodulon Dear Robert We promised some feedback after our trip and the fact=it has taken a few days shows how well it went. The easiest thing is to cop= what I have said to Anthony Bolton and our other shareholders:<=p> Just to let you have some Breaking News as the BBC=would say! We have had a superb trip to Phoenix to visit Dr Dan von Hoff - h= is as I am sure you know the Key Opinion Leader for pancreatic cancer and h=s just published the data from the Gem/Abraxane study which has helped Celgene shares rise nicely! I am su=e I gave you a copy of the TIME article in which he features heavily. The good news is that he loves our project and the=data we showed him both in mouse and human models as well as the early data=on our own ongoing pancreatic cancer trial, so much so that he has agreed t= become our Chief Investigator for a new phase 3 trial in pancreas. EFTA_R1_02108903 EFTA02708214  I think you will agree that this is a huge vote of=confidence in our project and especially as we will do this in the US. All t=at is needed is to fund the study and we would look for some $10million - t=ere would be a lot of subsidy from Dan's group so this is a cheap study for a phase3 pancreas. The r=mifications would extend to many other cancers as well as to the inflammato=y brain disorders which include Alzheimer's etc. This is very something wit= which your group could help. In any case, we are delighted and our share price,=were we a public company, would certainly have risen nicely this week= I hope you agree that our valuation is perhaps not so=daft as it sounds and there is room for more growth. Certainly, shares in a=l the companies that have immunotherapy in their portfolio have done very w=ll recently and especially Celgene and BMS, and it is highly likely that there will be a collaboration with us=and Celgene. We will arrange to meet up but the next couple of wee=s are silly as we need to consolidate on the trip and plot our strategy and=not least raise the funds - the £9million I want will cover this nicel= and I am confident I will get it. Let's speak in a couple of weeks and fix a date to me=t up? Yours aye Charles Charles Akle BSc MS FRCS London Clinic Cancer Centre - B2 22 Devonshire Place London W1G 6JA T: M: 2 EFTA_R1_02108904 EFTA02708215  F: This email message (including any documents, files, o= previous email messages embedded in it or attached to it) is intended only=for designated recipients. Some or all of the information may be confi=ential and not intended for public dissemination. If you have received the message in error please notify the s=nder and then delete the full content from your system without reading=it. Unauthorised use, copying, printing, distribution or reproduction of th= information contained in or attached to this message is not permitted. <tn.jpeg> =/html>= 3 EFTA_R1_02108905 EFTA02708216